Claims for Patent: 5,989,906

Summary for Patent: 5,989,906

Title:	Method and reagent for inhibiting P-glycoprotein (mdr-1-gene)
Abstract:	An enzymatic RNA molecule which specifically cleaves mRNA encoded by an mdr-1 gene.
Inventor(s):	Thompson; James D. (Solon, OH)
Assignee:	Ribozyme Pharmaceuticals, Inc. (Cleveland, OH)
Application Number:	08/192,942
Patent Claims:	1. A catalytic RNA molecule which is active to specifically cleave the sequence shown as any of SEQ. ID. NOS. 1-9. 2. The catalytic RNA molecule of claim 1 wherein said RNA molecule is in a hammerhead motif. 3. The catalytic RNA molecule of claim 1 wherein said RNA molecule is in a hairpin, hepatitis Delta virus, group 1 intron, or RNaseP RNA motif. 4. A mammalian cell comprising a catalytic RNA molecule of any of claims 1, 2 or 3. 5. The cell of claim 4, wherein said cell is a human cell. 6. An expression vector comprising nucleic acid encoding the catalytic RNA molecule of any of claims 1 or 2, in a manner which allows expression of that catalytic RNA molecule within a mammalian cell.

Details for Patent 5,989,906

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Llc	INTRON A	interferon alfa-2b	For Injection	103132	June 04, 1986		2014-02-07
Merck Sharp & Dohme Llc	INTRON A	interferon alfa-2b	For Injection	103132			2014-02-07
Merck Sharp & Dohme Llc	INTRON A	interferon alfa-2b	Injection	103132			2014-02-07